U.S. markets open in 3 hours 35 minutes

argenx SE (ARGX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
376.87+7.42 (+2.01%)
At close: 04:00PM EDT
375.71 -1.16 (-0.31%)
After hours: 04:17PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close369.45
Bid379.19 x 800
Ask380.69 x 900
Day's Range366.08 - 379.05
52 Week Range249.50 - 403.77
Avg. Volume251,359
Market Cap20.883B
Beta (5Y Monthly)0.79
PE Ratio (TTM)N/A
EPS (TTM)-11.53
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est427.37
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for ARGX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • argenx SE
    Daily – Vickers Top Buyers & Sellers for 06/23/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    3 months agoArgus Research
View more
  • Benzinga

    Argenx Seeks FDA Nod For Its Flagship Neuromuscular Treatment Formulated For Subcutaneous Injection

    Argenx SE (NASDAQ: ARGX) has submitted an FDA marketing application for SC efgartigimod for adult patients with generalized myasthenia gravis (gMG). SC efgartigimod is co-formulated with recombinant human hyaluronidase PH20 (rHuPH20), Halozyme Therapeutics Inc's (NASDAQ: HALO) ENHANZE drug delivery technology. ENHANZE facilitates the subcutaneous injection delivery of biologics that are typically administered via intravenous (IV) infusion. Related: Argenx's Drug Scores European Approval For Musc

  • GlobeNewswire

    argenx to Highlight Key Programs from Neuromuscular Franchise at Upcoming Medical Meetings

    Scientific presentations demonstrate argenx’s leadership in FcRn blockade and commitment to innovating for patients across multiple neuromuscular diseases Additional data from ADAPT+ open-label study support long-term safety of VYVGART® (efgartigimod alfa-fcab) for treatment of adult patients with generalized myasthenia gravis (gMG), who experienced consistent improvements in function and strength over multiple years Pooled data from ADAPT studies and real-world clinical setting suggest VYVGART

  • GlobeNewswire

    argenx Submits Biologics License Application to U.S. Food and Drug Administration for Subcutaneous Efgartigimod for Treatment of Generalized Myasthenia Gravis

    Submission package based on positive data from the Phase 3 ADAPT-SC trial demonstrating noninferiority of subcutaneous (SC) efgartigimod compared to intravenously administered VYVGART® (efgartigimod alfa-fcab) based on total immunoglobulin G (IgG) reduction at day 29 Amsterdam, the Netherlands – September 21, 2022 – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced the submission